Bringing new molecules to First Time in Human (FTIH) studies as rapidly as possible is critical in today’s marketplace. With expanded numbers of target molecules and an increasing pressure to bring new molecules to market quickly, rapidly confirming proof of concept in the earliest phases of development is essential. Delays in the development of your product can translate into millions of dollars in lost profits. In addition, the costs of new Active Pharmaceutical Ingredients (API) are on the rise, particularly for biopharmaceutical molecules, and conserving this valuable resource can save you both time and money.

Patheon offers Quick to Clinic™ programs focused on bringing new molecules to FTIH studies as rapidly as possible while minimizing the amount of API required. Patheon uses the experience and scientific knowledge of its team of Pharmaceutical Development Services (PDS) scientists combined with a number of tools and strategies to achieve these results.

Patheon’s Quick to Clinic™ toolbox includes:

	Simplified Dosage Forms		Nanoparticle Technology
	Miniaturization Equipment		Statistical Design of Experiment (DOE)
	Integrated Analytical Development		Extensive Scientific Experience & Expertise

Contact us to learn more about how Patheon can help bring your new molecule to clinic faster using less API.